Newsfeeds - Spark Newswire

3 minute read

Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August

September 16, 10:20 AM

Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also fell, dropping 0.62% to 4,453.04.

AERI

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

September 16, 8:15 AM

ACER

5 minute read

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study

By Shanthi Rexaline

September 16, 7:48 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)

ACHL

2 minute read

20 Stocks Moving in Thursday’s Pre-Market Session

By Lisa Levin

September 16, 7:40 AM

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) rose 59.7% to $51.30 in pre-market trading. IronNet Cybersecurity emerged as the most-discussed stock on Reddit’s r/WallStreetBets forum as of Wednesday night.

AERI

1 minute read

Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial

By Vandana Singh

September 16, 5:59 AM

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced topline results of its Phase 2b COMET-1 study evaluating AR-15512 (TRPM8 Agonist) ophthalmic solution for dry…

AERI

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

September 15, 4:58 PM

Gainers

AERI

2 minute read

Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms And Signs In Successful Phase 2b Clinical Study For The Treatment Of Dry Eye Disease

By Benzinga Newsdesk

September 15, 4:03 PM

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle

AERI

1 minute read

USPTO Site Shows Aerie Pharmaceuticals Granted Patent ‘Compounds, compositions and methods for treatment of myopia’

By Bill Haddad

September 14, 12:22 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5484&f=G&l=50&d=PTXT&p=110&S1=20210914&OS=20210914&RS=20210914

AERI

2 minute read

Earnings

Looking into Aerie Pharmaceuticals’s Return on Capital Employed

By Benzinga Insights

August 20, 2:37 PM

After pulling data from Benzinga Pro it seems like during Q2, Aerie Pharmaceuticals (NASDAQ:AERI) posted sales of $27.18 million. Earnings were up 7.94%, but Aerie Pharmaceuticals still reported an overall loss of $31.50 million.

AERI

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

August 10, 4:52 PM

Gainers

AERI